p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy
- 8 July 2004
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 210 (1) , 101-109
- https://doi.org/10.1016/j.canlet.2004.01.006
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal CancerNew England Journal of Medicine, 2000
- Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal CancersJNCI Journal of the National Cancer Institute, 1999
- Genetic instabilities in human cancersNature, 1998
- 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.Journal of Clinical Oncology, 1998
- Genetic instability in colorectal cancersNature, 1997
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- p53 mutations in colorectal cancer.Proceedings of the National Academy of Sciences, 1990
- A genetic model for colorectal tumorigenesisCell, 1990
- Convention on nomenclature for DNA cytometryCancer Genetics and Cytogenetics, 1984